Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 56

1.

Comparison of Outcomes in Patients With Muscle-invasive Bladder Cancer Treated With Radical Cystectomy Versus Bladder Preservation.

Zhong J, Switchenko J, Jegadeesh NK, Cassidy RJ, Gillespie TW, Master V, Nieh P, Alemozaffar M, Kucuk O, Carthon B, Filson CP, Bilen MA, Jani AB.

Am J Clin Oncol. 2018 Jun 16. doi: 10.1097/COC.0000000000000471. [Epub ahead of print]

PMID:
29912804
2.

Moving toward a more rational, evidence-based approach to PSA screening, diagnosis, and treatment of prostate cancer.

Filson CP.

Cancer. 2018 Jul 1;124(13):2684-2686. doi: 10.1002/cncr.31332. Epub 2018 May 21. No abstract available.

PMID:
29781113
3.

Quality of care and economic considerations of active surveillance of men with prostate cancer.

Filson CP.

Transl Androl Urol. 2018 Apr;7(2):203-213. doi: 10.21037/tau.2017.08.08. Review.

4.

Editorial Comment.

Henry MA, Filson CP.

J Urol. 2018 Aug;200(2):368. doi: 10.1016/j.juro.2018.03.137. Epub 2018 Apr 24. No abstract available.

PMID:
29698622
5.

Adoption of Prebiopsy Magnetic Resonance Imaging for Men Undergoing Prostate Biopsy in the United States.

Liu W, Patil D, Howard DH, Moore RH, Wang H, Sanda MG, Filson CP.

Urology. 2018 Jul;117:57-63. doi: 10.1016/j.urology.2018.04.007. Epub 2018 Apr 18.

PMID:
29679601
6.

Editorial Comment.

Filson CP.

J Urol. 2018 Jul;200(1):59. doi: 10.1016/j.juro.2017.11.155. Epub 2018 Apr 19. No abstract available.

PMID:
29679581
7.

Association Between Online Information-Seeking and Adherence to Guidelines for Breast and Prostate Cancer Screening.

Kim H, Filson C, Joski P, von Esenwein S, Lipscomb J.

Prev Chronic Dis. 2018 Apr 19;15:E45. doi: 10.5888/pcd15.170147.

8.

Cost considerations for systemic therapy for patients with advanced genitourinary malignancies.

Henry MA, Leung A, Filson CP.

Cancer. 2018 Jul 15;124(14):2897-2905. doi: 10.1002/cncr.31355. Epub 2018 Mar 26. Review.

PMID:
29579342
9.

Physician Reimbursement for Prostate Biopsies Falls as Procedures Shift From Offices to Facilities.

Henry MA, Howard DH, Davies BJ, Filson CP.

Urology. 2018 May;115:96-101. doi: 10.1016/j.urology.2018.02.008. Epub 2018 Mar 12.

PMID:
29545049
10.

Risk of Readmission After Uncomplicated Hospitalization After Radical Cystectomy.

Lorentz CA, Gilbert K, Alemozaffar M, Patil D, Filson CP.

Clin Genitourin Cancer. 2018 Aug;16(4):e705-e710. doi: 10.1016/j.clgc.2018.01.004. Epub 2018 Feb 2.

PMID:
29478962
11.

A novel preoperative inflammatory marker prognostic score in patients with localized and metastatic renal cell carcinoma.

Sekar RR, Patil D, Baum Y, Pearl J, Bausum A, Bilen MA, Kucuk O, Harris WB, Carthon BC, Alemozaffar M, Filson CP, Pattaras JG, Nieh PT, Ogan K, Master VA.

Asian J Urol. 2017 Oct;4(4):230-238. doi: 10.1016/j.ajur.2017.04.002. Epub 2017 May 10.

12.

In-bore MRI-guided biopsy: can it optimize the need for periodic biopsies in prostate cancer patients undergoing active surveillance? A pilot test-retest reliability study.

Elfatairy KK, Filson CP, Sanda MG, Osunkoya AO, Geller RL, Nour SG.

Br J Radiol. 2018 Apr;91(1084):20170603. doi: 10.1259/bjr.20170603. Epub 2018 Feb 13.

PMID:
29308912
13.

The Movember Foundation's GAP3 cohort: a profile of the largest global prostate cancer active surveillance database to date.

Bruinsma SM, Zhang L, Roobol MJ, Bangma CH, Steyerberg EW, Nieboer D, Van Hemelrijck M; Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium.

BJU Int. 2018 May;121(5):737-744. doi: 10.1111/bju.14106. Epub 2018 Jan 18.

PMID:
29247473
14.

Editorial Comment.

Filson CP.

Urology. 2018 Jan;111:84-85. doi: 10.1016/j.urology.2017.08.054. Epub 2017 Nov 22. No abstract available.

PMID:
29174272
15.

Comparative Cost Analysis: Teleurology vs Conventional Face-to-Face Clinics.

Zholudev V, Safir IJ, Painter MN, Petros JA, Filson CP, Issa MM.

Urology. 2018 Mar;113:40-44. doi: 10.1016/j.urology.2017.07.034. Epub 2017 Aug 2.

PMID:
28780298
16.

Decision Support with the Personal Patient Profile-Prostate: A Multicenter Randomized Trial.

Berry DL, Hong F, Blonquist TM, Halpenny B, Filson CP, Master VA, Sanda MG, Chang P, Chien GW, Jones RA, Krupski TL, Wolpin S, Wilson L, Hayes JH, Trinh QD, Sokoloff M, Somayaji P.

J Urol. 2018 Jan;199(1):89-97. doi: 10.1016/j.juro.2017.07.076. Epub 2017 Jul 25.

PMID:
28754540
17.

Variation in Use of Prostate Biopsy Following Changes in Prostate Cancer Screening Guidelines.

Henry MA, Howard DH, Davies BJ, Filson CP.

J Urol. 2017 Nov;198(5):1046-1053. doi: 10.1016/j.juro.2017.05.008. Epub 2017 May 6.

PMID:
28487099
18.

Editorial Comment.

Filson CP.

Urology. 2017 Jan;99:82. doi: 10.1016/j.urology.2016.07.046. Epub 2016 Oct 26. No abstract available.

PMID:
28341020
19.

Expert consensus document: Semantics in active surveillance for men with localized prostate cancer - results of a modified Delphi consensus procedure.

Bruinsma SM, Roobol MJ, Carroll PR, Klotz L, Pickles T, Moore CM, Gnanapragasam VJ, Villers A, Rannikko A, Valdagni R, Frydenberg M, Kakehi Y, Filson CP, Bangma CH; Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium.

Nat Rev Urol. 2017 May;14(5):312-322. doi: 10.1038/nrurol.2017.26. Epub 2017 Mar 14. Review.

20.

Surgical Margins in Nephron-Sparing Surgery for Renal Cell Carcinoma.

Laganosky DD, Filson CP, Master VA.

Curr Urol Rep. 2017 Jan;18(1):8. doi: 10.1007/s11934-017-0651-5. Review.

PMID:
28211006

Supplemental Content

Loading ...
Support Center